

# Chen-Hua Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8915368/publications.pdf>

Version: 2024-02-01

168  
papers

4,983  
citations

94433

37  
h-index

114465

63  
g-index

169  
all docs

169  
docs citations

169  
times ranked

4358  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 424-434.e5.	4.4	9
2	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , 2022, 71, 176-184.	12.1	28
3	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	4.4	14
4	Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1579-1587.	1.7	4
5	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	1.7	2
6	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	3.3	2
7	Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. <i>American Journal of Gastroenterology</i> , 2022, 117, 748-757.	0.4	15
8	Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis. <i>Journal of the Chinese Medical Association</i> , 2022, Publish Ahead of Print, .	1.4	0
9	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
10	Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2172-e2174.	5.8	6
11	Reply to: "Sofosbuvir and the risk of kidney dysfunction". <i>Journal of Hepatology</i> , 2021, 74, 257-258.	3.7	0
12	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021, 15, 338-349.	4.2	20
13	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
14	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	2.8	3
15	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 887-896.	2.0	7
16	Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 1924-1928.	0.4	6
17	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	2.8	10
18	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 575-588.	8.9	9

#	ARTICLE	IF	CITATIONS
19	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	4.2	4
20	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	10
21	Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. <i>Journal of the Formosan Medical Association</i> , 2021, , .	1.7	8
22	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 908-918.	3.7	20
23	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, , .	3.7	9
24	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	4.0	11
25	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 569-577.	3.1	18
26	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	3.9	24
27	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	5.1	5
28	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	5.8	30
29	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	3.7	49
30	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.4	19
31	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa397.	0.9	3
32	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	1.7	60
33	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	4.0	6
34	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.2	3
35	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	1.7	5
36	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	3.7	43

#	ARTICLE	IF	CITATIONS
37	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	3.3	8
38	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	2.0	21
39	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	7.7	17
40	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	1.7	69
41	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	3.3	4
42	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 554-561.	8.9	8
43	Sa1531 PERSISTENT ON-TREATMENT ALANINE AMINOTRANSFERASE ELEVATION (POAE) IN PATIENTS WITH CHRONIC HEPATITIS C RECEIVING INTERFERON (IFN) FREE DIRECT ACTING ANTIVIRALS (DAAS). <i>Gastroenterology</i> , 2020, 158, S-1322.	1.3	0
44	HCV reinfections after viral clearance among HIV-positive patients with recent HCV infection in Taiwan. <i>Liver International</i> , 2019, 39, 1860-1867.	3.9	28
45	THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis. <i>Journal of Hepatology</i> , 2019, 70, e225.	3.7	5
46	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , 2019, 34, 1882-1890.	3.9	14
47	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	4.2	27
48	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	1.3	83
49	Tu1501 - Ledipasvir/Sofosbuvir for 8, 12, Or 24 Weeks is Safe and Effective in Patients Undergoing Dialysis. <i>Gastroenterology</i> , 2019, 156, S-1344.	1.3	1
50	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1014-1023.	1.7	9
51	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	3.7	29
52	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	2.8	14
53	Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 115-116.	3.7	0
54	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2179-2186.	2.8	4

#	ARTICLE	IF	CITATIONS
55	FRI-240-Comparison of Abbott RealTime HCV genotype II, Abbott HCV genotype plus RUO with Roche Cobas HCV genotyping assays for hepatitis C virus genotyping. <i>Journal of Hepatology</i> , 2019, 70, e500.	3.7	0
56	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	2.8	7
57	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 117-118.	3.7	0
58	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	2.8	11
59	Editorial: nephrotoxicity and oral anti-viral therapy for HBV – facts or fiction?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 229-230.	3.7	1
60	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	1.7	11
61	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	3.7	11
62	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1690-1698.	3.7	23
63	Fibrosis index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1480-1489.	3.7	19
64	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	4.0	67
65	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	7.3	18
66	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	2.8	16
67	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	5.8	27
68	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	2.8	28
69	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	2.5	13
70	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1290-1300.	3.7	43
71	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	3.3	22
72	High mortality rate in HBV-related cirrhosis patients with HEV superinfection. <i>Journal of Hepatology</i> , 2018, 68, S753.	3.7	0

#	ARTICLE	IF	CITATIONS
73	Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 407-409.	1.7	6
74	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16
75	Urgency to treat patients with chronic hepatitis C in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 966-974.	2.8	23
76	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.4	44
77	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	3.3	13
78	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.9	43
79	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	1.0	18
80	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	7.3	38
81	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	1.7	6
82	Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction?. <i>Translational Cancer Research</i> , 2016, 5, S192-S195.	1.0	0
83	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	3.3	7
84	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	3.3	8
85	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	3.3	13
86	Microevolution of the hepatitis B virus genome in hepatitis B antigen-positive carriers: Comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	2.8	2
87	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 705-713.	2.2	37
88	The synthesis of TiC/TiNi powders and bulk materials. <i>Materials Research Innovations</i> , 2015, 19, S1-113-S1-117.	2.3	0
89	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	12.1	39
90	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	4.2	12

#	ARTICLE	IF	CITATIONS
91	Sorafenib and SC-1 Exhibit Anti-fibrotic Effects Through Signal Transducer and Activator of Transcription 3 Inhibition. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1386.	4.4	0
92	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	7.1	65
93	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	4.0	7
94	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	3.9	62
95	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	3.7	49
96	Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 923-928.	1.7	29
97	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	12.1	105
98	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	2.8	7
99	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	3.9	14
100	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	2.8	27
101	P639 SPONTANEOUS SEROCLEARANCE OF HBsAg IN HEPATITIS B VIRUS/HEPATITIS C VIRUS DUALY INFECTED PATIENTS: A 10-YEAR FOLLOW-UP. <i>Journal of Hepatology</i> , 2014, 60, S281.	3.7	0
102	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	5.1	14
103	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	2.8	16
104	Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. <i>International Journal of Nanomedicine</i> , 2014, 9, 2051.	6.7	19
105	Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2014, 160, 581.	3.9	1
106	Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2014, 160, 581.	3.9	3
107	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	4.2	6
108	IL28B Genotype on HCV Infection in Asia. <i>Current Hepatitis Reports</i> , 2013, 12, 149-156.	0.3	3

#	ARTICLE	IF	CITATIONS
109	The Use of Transient Elastography in Liver Disease. <i>Journal of Medical Ultrasound</i> , 2013, 21, 179-180.	0.4	0
110	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	7.3	66
111	Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. <i>Journal of Clinical Virology</i> , 2013, 56, 293-298.	3.1	20
112	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	4.0	45
113	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	7.3	47
114	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	7.1	57
115	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	7.3	227
116	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	1.0	9
117	Pegylated Interferon- $\alpha$ 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	3.9	91
118	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	2.5	19
119	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	1.0	41
120	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	4.0	47
121	Association of hepatitis C virus infection and malnutrition-inflammation complex syndrome in maintenance hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1176-1183.	0.7	12
122	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	1.0	23
123	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	1.3	469
124	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	4.2	18
125	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012, 19, e48-57.	2.0	56
126	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	7.3	130



#	ARTICLE	IF	CITATIONS
127	Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin. <i>PLoS ONE</i> , 2012, 7, e52048.	2.5	23
128	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	1.0	5
129	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- $\alpha$ -2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	1.0	91
130	Treatment of hepatitis C virus infection in patients with end-stage renal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 228-239.	2.8	80
131	Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1348-1353.	2.8	6
132	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	2.0	21
133	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	4.2	13
134	Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 1212-1220.	5.0	10
135	Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load. <i>Journal of Infection</i> , 2011, 62, 448-455.	3.3	70
136	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1057-1065.	4.5	77
137	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3719-3724.	7.1	56
138	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	1.0	80
139	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 970-977.	2.8	31
140	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2010, 51, 541-549.	5.8	36
141	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	4.0	46
142	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	5.2	32
143	Pegylated interferon $\alpha$ -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	12.1	27
144	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	4.2	31

#	ARTICLE	IF	CITATIONS
145	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	34
146	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	1.3	211
147	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	4.0	28
148	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.4	6
149	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	10
150	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	1.0	35
151	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	3.9	86
152	Metabolic profiles in patients with chronic hepatitis C: a caseâ€“control study. <i>Hepatology International</i> , 2008, 2, 250-257.	4.2	33
153	Pegylated Interferonâ€“2a plus Ribavirin for Treatmentâ€“Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	5.8	177
154	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	7.3	29
155	Thyrotoxic Periodic Paralysis Induced by Pegylated Interferon Alpha Plus Ribavirin for Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 112-113.	2.2	2
156	Pegylated interferon Â-2a versus standard interferon Â-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	12.1	69
157	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	4.4	29
158	Enterolith ileus in a patient with jejunal diverticulosis: Sonographic findings. <i>Journal of Clinical Ultrasound</i> , 2007, 35, 169-173.	0.8	7
159	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1098-1103.	2.8	76
160	Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges (Editorial). <i>Nephrology</i> , 2007, 12, 8-10.	1.6	5
161	Splenic vein thrombosis and <i>Klebsiella pneumoniae</i> septicemia after endoscopic gastric variceal obturation therapy with N-butyl-2-cyanoacrylate. <i>Gastrointestinal Endoscopy</i> , 2006, 63, 336-338.	1.0	22
162	Successful colonoscopic drainage of appendiceal pus in acute appendicitis. <i>Gastrointestinal Endoscopy</i> , 2006, 64, 1011-1012.	1.0	9

#	ARTICLE	IF	CITATIONS
163	Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. <i>Liver International</i> , 2006, 26, 1087-1094.	3.9	55
164	Gastroduodenal Corrosive Injury After Oral Zinc Oxide. <i>Annals of Emergency Medicine</i> , 2006, 47, 296.	0.6	12
165	Impact of Rapid Entry and Accelerated Care at Triage on Reducing Emergency Department Patient Wait Times, Length of Stay, and Rate of Leaving Without Being Seen. <i>Annals of Emergency Medicine</i> , 2006, 47, 295.	0.6	1
166	Selective Transmission of Hepatitis C Virus Quasi Species through a Needlestick Accident in Acute Resolving Hepatitis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1254-1259.	5.8	12
167	Biliary hamartomas with delayed <sup>99m</sup> Tc-diisopropyl iminodiacetic acid clearance. <i>Journal of Gastroenterology</i> , 2005, 40, 540-544.	5.1	6
168	Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct-acting antiviral-induced sustained virologic response. <i>Advances in Digestive Medicine</i> , 0, , .	0.2	3